XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2024
May 10, 2024
Document Information [Line Items]    
Document Type 10-Q/A  
Amendment Flag true  
Amendment Description In this Amendment No. 1 on Form 10-Q/A (“Amendment No. 1”), unless the context requires otherwise, “Eledon”, the “Company”, “we”, “our", and “us” means Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) and all of its wholly-owned subsidiaries.This Amendment No. 1 amends the Quarterly Report on Form 10-Q of Eledon Pharmaceuticals, Inc. for the three months ended March 30, 2024 as filed with the Securities and Exchange Commission (the “SEC”) on May 15, 2024 (the “Original Report”). On May 20, 2024, the partners and professional staff of KMJ Corbin & Company LLP (“KMJ”) departed KMJ, which was engaged as the independent registered public accounting firm of the Company and joined Crowe LLP (“Crowe”). In connection with this transition, the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) dismissed KMJ as the Company's independent registered public accounting firm on July 10, 2024. On July 10, 2024, following the dismissal of KMJ, the Company, through and with the approval of its Audit Committee, appointed Crowe as its independent registered public accounting firm. In the course of preparing the Company’s unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2024, the Company, in consultation with Crowe, determined that a correction was necessary with respect to the Company’s reporting and recording of the fair value of (i) certain common stock warrants (the “Common Warrants”) issued by the Company in May 2023 pursuant to a Securities Purchase Agreement dated as of April 28, 2023 by and among the Company and certain institutional and accredited investors (the “Securities Purchase Agreement”), and (ii) the potential issuance of pre-funded warrants in lieu of additional shares of common stock, $0.001 par value per share (the “Subsequent Closing Warrants”), issuable by the Company in a second closing and a third closing of the Securities Purchase Agreement contingent upon the satisfaction or waiver of certain specified conditions set forth therein. This correction relates to a determination that the Common Warrants and the Subsequent Closing Warrants do not meet the conditions to be classified as equity instruments under Accounting Standards Codification 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity,” and must instead be recorded as liabilities on the Company’s consolidated balance sheet at their fair value for each reporting period.On August 13, 2024, the Company’s management and the Audit Committee concluded that the previously issued (i) audited consolidated financial statements as of and for the fiscal year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 28, 2024 and amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 26, 2024 (together, the “2023 10-K”), and (ii) unaudited condensed consolidated financial statements as of and for (a) the three months ended March 31, 2024 included in the Original Report, (b) the three and nine months ended September 30, 2023 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023 and (c) the three and six months ended June 30, 2023 included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023 (together, the “Impacted Reports”) were each materially misstated. As a result, the Company’s management and the Audit Committee further determined on August 13, 2024 that the Impacted Reports require restatement (the "Restatement") and should no longer be relied upon. In connection with this Restatement of the Company’s previously-filed consolidated financial statements, the Company has also determined that a material weakness existed in its internal control over financial reporting as disclosed in Item 4. Controls and Procedures of this Amendment No. 1. In addition, KMJ notified the Company on August 13, 2024 that its Report of Independent Registered Public Accounting Firm dated March 28, 2024 on the consolidated financial statements of the Company as of and for the year ended December 31, 2023 should no longer be relied on.The Company has not filed, and does not intend to file, amendments to the Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023 or September 30, 2023 (the “Impacted 2023 Quarterly Reports”). Accordingly, investors should rely only on the financial information and other disclosures regarding these restated periods included in Amendment No. 2 to the 2023 Form 10-K that the Company has filed with the SEC. The financial information that has been previously filed or otherwise reported for the periods covered by the Impacted Reports is superseded by the information in Amendment No. 2 to the 2023 Form 10-K (as to the fiscal year ended December 31, 2023 and, solely with respect to the information included under the caption “Restatement of Interim Financial Information” in Note 13 of the Notes to Consolidated Financial Statements included in Amendment No. 2 to the 2023 Form 10-K, as to the information included in the Impacted 2023 Quarterly Reports), as well as by this Amendment No. 1 (as to the three months ended March 31, 2024 included in the Original Report), as applicable. The errors did not result in any impact on the Company’s cash and short-term investment position, cash runway, or operations.This Amendment No. 1 presents the Original Report, as amended and restated to date, with further modifications as necessary to reflect the Restatement. The following items have been amended to reflect the Restatement:•Item 1. Financial Information•Item 2. Management’s discussion and analysis of financial condition and results of operations.•Item 4. Controls and Procedures•Item 1A. Risk FactorsIn addition, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Item 6 of Part II of the Original Report is being amended and restated solely to include as exhibits the certifications of our principal executive officer and principal financial officer required by Rule 13a-14(a) under the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350). Except as otherwise expressly noted herein, this Amendment No. 1 does not amend, modify or update any other information set forth in the Original Report. Furthermore, this Amendment No. 1 does not change any previously reported financial results, except as necessary to reflect the Restatement, nor does it reflect events occurring after the filing date of the Original Report. Information not affected by this Amendment No. 1 remains unchanged and reflects the disclosures made at the time the Original Report was filed. Accordingly, this Amendment No. 1 should be read in conjunction with our filings made with the SEC subsequent to the filing of the Original Report, including any amendment to those filings.  
Document Period End Date Mar. 31, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Trading Symbol ELDN  
Entity Registrant Name ELEDON PHARMACEUTICALS, INC.  
Entity Central Index Key 0001404281  
Entity Current Reporting Status Yes  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   38,506,614
Entity File Number 001-36620  
Entity Tax Identification Number 20-1000967  
Entity Address, Address Line One 19800 MacArthur Blvd  
Entity Address, Address Line Two Suite 250  
Entity Address, City or Town Irvine  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92612  
City Area Code (949)  
Local Phone Number 238-8090  
Document Quarterly Report true  
Document Transition Report false  
Entity Incorporation, State or Country Code DE  
Title of 12(b) Security Common Stock, $0.001 par value  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
Former Address [Member]    
Document Information [Line Items]    
Entity Address, Address Line One 19900 MacArthur Boulevard  
Entity Address, Address Line Two Suite 550  
Entity Address, City or Town Irvine  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92612